Back to Leadership

V. Bryan Lawlis

  • Director, Aeglea BioTherapeutics, Inc.
  • Director, Geron Corporation


  • Compensation
  • Science and Technology


Bryan Lawlis, Ph.D. joined our Board in June 2007. Dr. Lawlis served as the President and CEO of Itero Biopharmaceuticals, LLC, a private holding company that held the assets of Itero Biopharmaceuticals, Inc., a private biotechnology company, from August 2011 to September 2017. Dr. Lawlis co-founded and served as President and CEO of Itero Biopharmaceuticals, Inc. from 2006 until it discontinued operations in August 2011.

Dr. Lawlis served as President and CEO of Aradigm Corporation, a public pharmaceutical company, from August 2004 to August 2006, and served on its board from February 2005 to August 2006, continuing in both capacities until August 2006. Dr. Lawlis previously served as Aradigm’s President and Chief Operating Officer from June 2003 to August 2004 and its Chief Operating Officer from November 2001 to June 2003. Prior to his time at Aradigm, Dr. Lawlis co-founded Covance Biotechnology Services, a contract biopharmaceutical manufacturing operation, and served as its President and CEO from 1996 to 1999, and as its Chairman from 1999 to 2001, when it was sold to Diosynth RTP, Inc., a division of Akzo Nobel, NV. Dr. Lawlis was employed at Genencor, Inc., a biotechnology company, and Genentech, Inc. from 1981 to 1996. Dr. Lawlis’ last position at Genentech, Inc. was Vice President of Process Sciences.

Dr. Lawlis serves on the boards of Aeglea BioTherapeutics, Inc. until June 2022and Geron Corporation, both public biopharmaceutical companies. Dr. Lawlis previously served on the board of Coherus BioSciences from January 2004 until June 2019. Dr. Lawlis currently holds a board position at 1Cbio, Inc., a private company and serves as an advisor to Phoenix Venture Partners, a venture capital firm focusing on manufacturing technologies and material sciences technologies. Dr. Lawlis also serves on the Manufacturing Advisory Boards of Allakos, Inc. and Pyxis Oncology and on the Scientific Advisory Boards of Comera Life Sciences (formerly ReForm Biologics), Absci Corp. and Coherus BioSciences in addition to advising W.L. Gore and Associates and Convergent Ventures.

Dr. Lawlis holds a B.A. in microbiology from the University of Texas at Austin, and a Ph.D. in Biochemistry from Washington State University.